Michael Migus

Associate
Email    PDF    VCard
P: 416-593-3978
F: 416-594-2435
  • Called to the Bar of Ontario, 2007
  • LL.B., Osgoode Hall Law School, 2006
  • M.Biotech, University of Toronto, 2003
  • B.Sc., (Honours), University of Toronto, 2001
Michael Migus
 Overview

Michael’s practice is focused on intellectual property (“IP”) law, with an emphasis on patent law in the pharmaceutical and biotechnology industries. 

Michael regularly advises clients on issues arising throughout the product life cycle, including providing freedom to operate and patent validity opinions to aid with product development, representing clients in proceedings under the Patented Medicines (Notice of Compliance) Regulations to facilitate product launch, and representing clients in post-market patent disputes.  

Prior to joining Blaney McMurtry LLP, Michael acted as the in-house Canadian IP counsel for a multinational pharmaceutical company. In this role Michael supported the Business Development, Market Access, Marketing, Portfolio and Regulatory Groups, advising senior management on IP, commercial and regulatory issues relating to both the generic and branded business. 

 Education
  • LL.B., Osgoode Hall Law School, 2006
  • M.Biotech, University of Toronto, 2003
  • B.Sc., (Honours), University of Toronto, 2001
 Practice Areas  Called to the Bar
  • Called to the Bar of Ontario, 2007

Recognition

 Speaking

Speaking

  • Lecturer, Seneca College Pharmaceutical Regulatory Affairs and Quality Operations Program: Introduction to Pharmaceutical Regulatory Affairs Course
 Publications

Publications

  • Co-Author, "International variability in the reimbursement of cancer drugs by publicly funded drug programs" Curr Oncol. 2012 Jun;19(3):e165-76
 News
 Memberships

Memberships

  • Law Society of Ontario
  • Ontario Bar Association
DISCLAIMER

Thank you for your interest in contacting us by email.

Please be aware that contacting us via e-mail does not mean that the firm is acting for the sender of the e-mail. People do not become clients unless and until the firm agrees to act and that representation will be confirmed in a retainer agreement or retainer letter, in accordance with our usual policies. Unless you are an existing client, no information provided in an e-mail will be considered confidential. We ask that you do not send us specific questions on any matter until you receive confirmation that we are able to represent you.